Urolithins for improving cardiac function and health
AssigneeAmazentis SA
InventorsDavide D'Amico, Anurag Singh, Christopher L. Rinsch
Life of this patent
Estimating the term…
Abstract
Disclosed are methods and compositions for use in improving cardiac function and health. The methods and compositions are based on urolithins.
Claims89
A method of improving cardiac function, comprising administering to a mammal in need thereof an effective amount of a urolithin;
- wherein the effective amount of the urolithin is about 10 mg/kg to about 30 mg/kg;
- and the mammal has a myocardial infarction, coronary artery disease (CAD), congestive heart failure (CHF), angina, stroke, arrhythmia, fibrillation, peripheral arterial disease (PAD), or a cardiac or arterial disorder.
A method of improving cardiac function, comprising administering to a mammal in need thereof an effective amount of a urolithin;
- wherein the effective amount of the urolithin is about 10 mg/kg to about 30 mg/kg.
A method of protecting cardiac function, comprising administering to a mammal in need thereof an effective amount of a urolithin;
- wherein the effective amount of the urolithin is about 10 mg/kg to about 30 mg/kg.
A method of decreasing the rate of decline in cardiac function, comprising administering to a mammal in need thereof an effective amount of a urolithin;
- wherein the effective amount of the urolithin is about 10 mg/kg to about 30 mg/kg.
A method of preventing decline in cardiac function, comprising administering to a mammal in need thereof an effective amount of a urolithin;
- wherein the effective amount of the urolithin is about 10 mg/kg to about 30 mg/kg.
A method of managing or treating peripheral arterial disease (PAD), comprising administering to a mammal in need thereof an effective amount of a urolithin;
- wherein the effective amount of the urolithin is about 10 mg/kg to about 30 mg/kg.
A method of managing or improving tissue oxygenation, comprising administering to a mammal in need thereof an effective amount of a urolithin;
- wherein the effective amount of the urolithin is about 10 mg/kg to about 30 mg/kg.
A method of improving a cardiac output, comprising administering to a mammal in need thereof an effective amount of a urolithin;
- wherein the effective amount of the urolithin is about 10 mg/kg to about 30 mg/kg.
A method of increasing ventricular ejection fraction, comprising administering to a mammal in need thereof an effective amount of a urolithin;
- wherein the effective amount of the urolithin is about 10 mg/kg to about 30 mg/kg.
A method of increasing heart systolic function, comprising administering to a mammal in need thereof an effective amount of a urolithin;
- wherein the effective amount of the urolithin is about 10 mg/kg to about 30 mg/kg.
A method of increasing heart systolic function and skeletal muscle function, comprising administering to a mammal in need thereof an effective amount of a urolithin;
- wherein the effective amount of the urolithin is about 10 mg/kg to about 30 mg/kg;
- and the mammal is an aging mammal.
A method of maintaining, supporting, or improving blood circulation, comprising administering to a mammal in need thereof an effective amount of a urolithin;
- wherein the effective amount of the urolithin is about 10 mg/kg to about 30 mg/kg.
A method of maintaining, supporting, or improving heart function, comprising administering to a mammal in need thereof an effective amount of a urolithin;
- wherein the effective amount of the urolithin is about 10 mg/kg to about 30 mg/kg.
A method of maintaining, supporting, or improving heart muscle function, comprising administering to a mammal in need thereof an effective amount of a urolithin;
- wherein the effective amount of the urolithin is about 10 mg/kg to about 30 mg/kg.
Dependencies are inferred from the claim text.